Cell cycle regulators in bladder cancer: A multivariate survival study with emphasis on p27Kip1

Human Pathology

Volumn 31, Issue 6, 2000, Pages 751-760

  Korkolopoulou, Penelope ^a,b,c   Christodoulou, Panagiota ^a,b   Konstantinidou, Anastasia E ^a,b   Thomas Tsagli, Euphemia ^a,b   Kapralos, Panagiotis ^a,b   Davaris, Panagiotis ^a,b  

^a UNIVERSITY OF ATHENS   (Greece)

^b Asklepeion Hospital   (Greece)

^c NONE   (Greece)

Author keywords

Bladder cancer; p16; p21; p27; pRb

Indexed keywords

PROTEIN P27;

ADULT; AGED; ARTICLE; BLADDER CANCER; CANCER GRADING; CANCER GROWTH; CANCER SURVIVAL; CARCINOGENESIS; CELL CYCLE; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; PROGNOSIS; PROTEIN EXPRESSION;

EID: 0033932176     PISSN: 00468177     EISSN: None     Source Type: Journal    
DOI: 10.1053/hupa.2000.8227     Document Type: Article

References (42)

1. Clurman B.E. Roberts J.M. Cell cycle control: An overview Vogelstein B. Kinzler K.W. The Genetic Basis of Human Cancer 1998 McGraw Hill New York, NY 175 192
2. Sherr C.J. Cancer cell cycles Science 274 1996 1672 1677
3. Granna X. Reddy E.P. Cell cycle control in mammalian cells: role of cyclins, cyclin-dependent kinases (CDKs), growth suppressor genes and cyclin dependent kinase inhibitors (CKls) Oncogene 11 1995 211 219
4. Luo Y. Hurwitz J. Massague J. Cell-cycle inhibition by independent CDK and PCNA binding domains in p21/Cipl Nature 375 1995 159 161
5. El-Deiry W.S. Tokino T. Velculescu V.E. WAFI, a potential mediator of p53 tumor suppression Cell 75 1993 817 825
6. Polyak K. Lee M. Erjument-Bromage H. Cloning of p27 Kipl, a cyclin-dependent kinase inhibitor and a potential mediator of extracellular antimitogenic signals Cell 78 1994 59 66
7. Sherr C.J. Roberts J.M. Inhibitors of mammalian G1 cyclin-dependent kinases Genes Dev 9 1995 1149 1163
8. Toyoshima H. Hunter T. p27, a novel inhibitor of G1 cyclin-Cdk protein kinase activity, is related to p21 Cell 78 1994 67 74
9. Serrano M. Hannon G.J. Beach D. A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4 Nature 366 1993 704 707
10. Benedict W.F. Lerner S.P. Zhou J. Level of retinoblastoma protein expression correlates with p16 (MTSI/INK4A/CDKN2) status in bladder cancer Oncogene 18 1999 1197 1203
11. Sidransky D. von Eschenbach A. Tsai Y.C. Identification of p53 gene mutations in bladder cancers and urine samples Science 252 1991 706 709
12. Habuchi T. Ogawa O. Kaheki Y. Allelic loss of chromosome 17p in urothelial cancer: Strong association with invasive phenotype J Urol 148 1992 1595 1599
13. Xu H.-J. Cairns P. Hu S.X. Loss of RB protein expression in primary bladder cancer correlates with loss of heterozygosity at the RB locus and tumor progression Int J Cancer 53 1993 781 784
14. Akao T. Kakeli Y. Itoh N. A high prevalence of functional inactivation by methyladon modification of p16 INK4A/CDKN2/MTS1 gene in primary urothelial cancers Jpn J Cancer Res 88 1997 1078 1086
15. Reznikoff C.A. Belair C.D. Yeager T.R. A molecular genetic mo-del of tumor bladder cancer pathogenesis Semin Oncol 23 1996 571 584
16. Malcowicz S.B. Tomaszewski J.E. Linnenbach A.J. Novel p21 cipl/WAFI mutations in superficial and invasive transitional cell carcinomas Oncogene 13 1996 1831 1837
17. Kipl in muscle invasive bladder cancer Oncol Rep 6 1999 229 233
18. Stein J.P. Grossfeld G.D. Ginsberg D.A. Prognostic markers in bladder cancer: A contemporary review of the literature J Urol 160 1998 645 659
19. Pagano M. Tan S.W. Theodoras A.M. Role of ubiquitin-proteasome pathway in regulating the abundance of the cyclin dependent kinase inhibitor p27 Science 269 1995 682 685
20. Grignon D.J. Neoplasms of the urinary bladder Bostwick D.G. Eble J.N. Urologic Surgical Pathology 1997 Mosby St Louis, MO 252 253
21. rev 2 Hermanek R. Sobin L.H. TNM Classification of Malignant Tumours ed 3 1992 Berlin, Germany Springer
22. Smitz G. Schaafsma E. Kiemeney L. Microstaging of pTl transitional cell carcinoma of the bladder: Identification of subgroups with distinct risks of progression Urology 52 1998 1009 1013
23. Epstein J.I. Amin M.B. Reuter V.R. Bladder Consensus Conference Committee The World Health Organization (International Society of Urological Pathology) consensus classification of urothelial (transitional cell) neoplasms of the urinary bladder Am J Surg Pathol 22 1999 1435 1448
24. Norton A.J. Jordan S. Yeomans P. Brief, high-temperature heat denaturation (pressure cooking): A simple and effective method of antigen retrieval for routinely processed tissues J Pathol 173 1994 371 379
25. Korkolopoulou P. Christodoulou P. Kapralos P. The role of p53, MDM2 and c-erbB2 oncoproteins, epidermal growth factor receptor and proliferation markers in the prognosis of urinary bladder cancer Pathol Res Pract 193 1997 767 775
26. Lipponen P. Aaltomaa S. Eskelinen M. Expression of p21 (WAF1/Cip1) protein in transitional cell bladder tumours and its prognostic value Eur Urol 34 1998 237 243
27. Soini Y. Turpeenniemi-Hujonen T. Kemel D. p53 immunohistochemistry in transitional cell carcinomas and dysplasia of the urinary bladder correlates with disease progression Br J Cancer 68 1993 1029 1035
28. Kuczyk M.A. Machtens S. Bokemeyer C. Prognostic value of p27 Kipl and p21 WAF/Cip protein expression in muscle invasive bladder cancer Oncol Rep 6 1999 687 693
29. Poller D.N. Baxter K.J. Shepherd N.A. p53 and Rbl protein expression: Are they prognostically useful in colorectal cancer? Br J Cancer 75 1997 87 93
30. Cordon-Cardo C. Dalbagni G. Saez G.T. p53 mutations in human bladder cancer: genotypic versus phenotypic patterns Int J Cancer 56 1994 347 353
31. INK4 inactivation in non-small cell lung cancer lines Cancer Res 55 1995 6200 6209
32. Momand J. Zambetti G.P. Olson D.C. The MDM2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transaction Cell 69 1992 1237 1245
33. Sgambato A. Migaldi M. Faraglia B. Loss of p27Kip1 expression correlates with tumor grade and with reduced disease-free survival in primary superficial bladder cancers Cancer Res 59 1999 3245 3250
34. Esrig D. Elmajian D. Groshen S. Accumulation of nuclear p53 and tumour progression in bladder cancer N Engl J Med 331 1994 1259 1264
35. Jung J.-M. Bruner J.M. Ruan S. Increased levels of p21 (WAF1/CIP1) in human brain tumors Oncogene 11 1995 2021 2028
36. Ohtani M. Isozaki H. Fujii K. Impact of the expression of cyclin-dependent kinase inhibitor p27Kip1 and apoptosis in tumor cells on the overall survival of patients withnon-early stage gastric carcinoma Cancer 85 1999 1711 1718
37. Moller M.B. Skjodt K. Mortensen L.S. Clinical significance of cyclin-dependent kinase inhibitor p27Kip1 expression and proliferation in non-Hodgkin's lymphoma: Independent prognosticvalue of p27kip1 Br J Haematol 105 1999 730 736
38. Tsihlias J. Kapusta L.R. Slingerlard J. The prognostic significance of altered cyclin-dependent kinase inhibitors in human cancer Annu Rev Med 50 1999 401 423
39. Aagaard L. Lukas J. Bartkova J. Aberrations of p161nk4 and retinoblastoma tumour-suppressor genes occur in distinct subsets of human cancer cell lines Int J Cancer 61 1995 115 120
40. Renisdottir I. Polyak K. Iavarone A. Kip/Cip and Ink4Cdk inhibitors cooperate to induce cell cycle arrest in response to TGF-beta Genes Dev 9 1995 1831 1845
41. Erlanson M. Portin C. Linderholm B. Expression of cyclin E and the cyclin-dependent kinase inhibitor p27 in malignant lymphomas: Prognostic implications Blood 92 1998 770 777
42. Pryor J.P. Factors influencing the survival of patients with transitional cell tumours of the urinary bladder Br J Urol 45 1973 586 591